Publish in this journal
Journal Information
Vol. 69. Issue 8.
Pages 798 (August 2016)
Share
Share
Download PDF
More article options
Vol. 69. Issue 8.
Pages 798 (August 2016)
Letter to the Editor
Full text access
SAMe-TT2R2 Score: Useful in All Patients With Nonvalvular Atrial Fibrillation?
Puntuación SAMe-TT2R2: ¿es útil en todos los pacientes con fibrilación auricular no valvular?
Visits
...
Carlos Escobara,
Corresponding author
, Vivencio Barriosb, José María Lobosc, Luis Prietod
a Servicio de Cardiología, Hospital Universitario La Paz, Madrid, Spain
b Servicio de Cardiología, Hospital Universitario Ramón y Cajal, Madrid, Spain
c Centro de Salud Jazmín, Atención Primaria Área 4, Madrid, Spain
d Bioestadística Médica, Universidad Católica San Antonio de Murcia, Murcia, Spain
Related content
Rev Esp Cardiol. 2016;69:453-410.1016/j.rec.2016.01.009
José M. Andreu-Cayuelas, Carmen M. Puche, César Caro-Martínez, Pedro J. Flores-Blanco, Mariano Valdés, Sergio Manzano-Fernández
Rev Esp Cardiol. 2016;69:79910.1016/j.rec.2016.04.026
José M. Andreu-Cayuelas, Carmen M. Puche, Pedro J. Flores-Blanco, Sergio Manzano-Fernández
Article information
Full Text
Bibliography
Download PDF
Statistics
Full Text
To the Editor,

The prevention of thromboembolic complications is essential in any patient with atrial fibrillation (AF). Currently, vitamin K antagonists (VKA) are the oral anticoagulation agents most widely employed in our patient population.1 Although effective, due to their narrow therapeutic window, the variability in patient response, and the high number of interactions, they require periodical monitoring of their anticoagulant activity and frequent dose adjustments.2,3 Recent studies have shown that anticoagulation control is inadequate in approximately 40% of the patients with nonvalvular AF treated with VKA in Spain, which puts them at greater risk for thromboembolic and/or bleeding complications.4 Thus, a priori identification of those patients at greater risk of poor control of the International Normalized Ratio (INR) would provide valuable information.

In this respect, some authors have reported the possible utility of the SAMe-TT2R2 score5 (female sex; age < 60 years; medical history [≥ 3 comorbidities: hypertension, diabetes mellitus, ischemic heart disease, peripheral arterial disease, heart failure, stroke, and/or lung, liver or kidney disease]; treatment [interacting drugs, such as amiodarone]; current tobacco use; and non-Caucasian race). In fact, a number of studies have validated this score, although in some cases, the ability to identify patients with poorer control was only moderate.6

We found the article by Andreu-Cayuelas et al7 to be very interesting. In their retrospective study involving 108 patients with nonvalvular AF who, having been hospitalized for heart failure, received VKA therapy after discharge, the authors observed that INR control was poor, and that the SAMe-TT2R2 score was not useful in discerning patients with good or poor anticoagulation with the treatment. These results were to be expected because, after any acute event, it is more difficult to achieve adequate INR control, mainly during the first few months, especially when adjustments in the medication are constantly being made after hospital discharge, as occurred in this case. In this setting, it would be difficult for any score to be of help in predicting which patients would prove to have poorer INR control.

However, the findings of this study highlight a relevant fact: that the SAMe-TT2R2 score is not useful in certain patients or situations, possibly because important factors that could affect the control of anticoagulation with VKA have not been included. The PAULA study is a multicenter trial conducted in the Spanish primary care setting for the purpose of determining the degree of anticoagulation control with VKA in 1524 patients with nonvalvular AF.4 Although this study found the SAMe-TT2R2 score to have a certain ability to predict poor anticoagulation control with these agents, this capacity was modest. However, the discriminatory value improved upon inclusion of certain factors such as high bleeding risk, multiple drug therapy, and dietary pattern.8

In short, although the SAMe-TT2R2 score is capable, to some degree, of predicting good or poor anticoagulation control with VKA, it is insufficient. Thus, it is necessary to design new, more comprehensive scores that are more efficient in identifying those patients who will show poorer control with these agents

References
[1]
G.Y. Lip, S.K. Rushton-Smith, S.Z. Goldhaber, D.A. Fitzmaurice, L.G. Mantovani, S. Goto, et al.
Does sex affect anticoagulant use for stroke prevention in nonvalvular atrial fibrillation? The prospective global anticoagulant registry in the FIELD-Atrial Fibrillation.
Circ Cardiovasc Qual Outcomes., 8 (2015), pp. S12-S20
[2]
R.G. Hart, L.A. Pearce, M.I. Aguilar.
Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.
Ann Intern Med., 146 (2007), pp. 857-867
[3]
V. Barrios, C. Escobar.
De los ensayos clínicos a la práctica clínica. Evidencias con rivaroxaban en el tratamiento anticoagulante del paciente con fibrilación auricular no valvular.
Semergen., (2016),
[4]
V. Barrios, C. Escobar, L. Prieto, G. Osorio, J. Polo, J.M. Lobos, et al.
Control de la anticoagulación en pacientes con fibrilación auricular no valvular asistidos en atención primaria en España. Estudio PAULA.
Rev Esp Cardiol., 68 (2015), pp. 769-776
[5]
S. Apostolakis, R.M. Sullivan, B. Olshansky, G.Y. Lip.
Factors affecting quality of anticoagulation control amongst atrial fibrillation patients on warfarin: the SAMe-TT2R2 score.
Chest., 144 (2013), pp. 1555-1563
[6]
M. Ruiz-Ortiz, V. Bertomeu, Á. Cequier, F. Marín, M. Anguita.
Validation of the SAMe-TT2R2 score in a nationwide population of nonvalvular atrial fibrillation patients on vitamin K antagonists.
Thromb Haemost., 114 (2015), pp. 695-701
[7]
J.M. Andreu-Cayuelas, C.M. Puche, C. Caro-Martínez, P.J. Flores-Blanco, M. Valdés, S. Manzano-Fernández.
La puntuación SAMe-TT2R2 no predice el tiempo en rango terapéutico tras un ingreso por insuficiencia cardiaca aguda en pacientes con fibrilación auricular.
Rev Esp Cardiol., 69 (2016), pp. 453-454
[8]
J.M. Lobos-Bejarano, V. Barrios-Alonso, J. Polo-García, C. Escobar-Cervantes, D. Vargas-Ortega, N. Marín-Montañés, et al.
Evaluation of SAMe-TT2R2 score and other clinical factors influencing the quality of anticoagulation therapy in non-valvular atrial fibrillation: a nationwide study in Spain.
Curr Med Res Opin., (2016),
Copyright © 2016. Sociedad Española de Cardiología
Idiomas
Revista Española de Cardiología (English Edition)

Subscribe to our newsletter

Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?